
What that powerful new Chinese AI app means for Washington
From Washington's perspective, the news raised an immediate policy alarm: It happened despite consistent, bipartisan efforts to stifle AI progress in China.
Both President Donald Trump and former President Joe Biden have made global competition — and, specifically, boxing out China — the centerpiece of their tech and AI policies. Somehow, a small and nimble Chinese company just jumped ahead anyway.
In tech terms, what freaked everyone out about DeepSeek's R1 model is that it replicated — and in some cases, surpassed — the performance of OpenAI's cutting-edge o1 product across a host of performance benchmarks, at a tiny fraction of the cost.
The business takeaway was straightforward. DeepSeek's success shows that American companies might not need to spend nearly as much as expected to develop AI models. That both intrigues and worries investors and tech leaders.
Some, like Microsoft CEO Satya Nadella, celebrated what they saw as the commodification of AI — a future where a wide range of companies can deploy the technology way more cheaply. Investors, clearly, had doubts: Quite a few tech stocks took a plunge, especially the highly valued chipmaker Nvidia, the biggest beneficiary of the current AI infrastructure rush.
The policy implications, though, are more complex. Washington's rampant anxiety about beating China has led to policies that the industry has very mixed feelings about.
On one hand, most tech firms hate the export controls that stop them from selling as much to the world's second-largest economy, and force them to develop new products if they want to do business with China. If DeepSeek shows those rules are pointless, many would be delighted to see them go away.
On the other hand, anti-China, protectionist sentiment has encouraged Washington to embrace a whole host of industry wishlist items, from a lighter-touch approach to AI rules to streamlined permitting for related construction projects. Does DeepSeek mean those, too, are failing? Or does it trigger a doubling-down?
DeepSeek's success truly seems to challenge the belief that the future of American AI demands ever more chips and power. That complicates Trump's interest in rapidly building out that kind of infrastructure in the U.S.
Why pour $500 billion into the Trump-endorsed 'Stargate' mega project — and why would the market reward companies like Meta that spend $65 billion in just one year on AI — if DeepSeek claims it only took $5.6 million and second-tier Nvidia chips to train one of its latest models? (U.S. industry insiders dispute the startup's figures and claim they don't tell the full story, but even at 100 times that cost, it would be a bargain.)
'The leading American companies are all part of this phenomenon whereby AI models continuously get smaller, faster, cheaper,' said Gregory Allen, director of the Wadhwani AI Center at the Center for Strategic and International Studies think tank.
He points out that DeepSeek techniques, powered by more impressive equipment, could also turbocharge American AI development: 'If Deepseek is kind of illustrative of the floor of capabilities being raised — what do you get for not that much money — in parallel, there is this phenomenon of the ceiling being raised.'
This first appeared in Digital Future Daily, POLITICO's afternoon newsletter about how tech and power are shaping our world. Subscribe here.
Tech companies, of course, love the recent bloom of federal support, and it's unlikely they'll drop their push for more federal investment to match anytime soon. Marc Andreessen, a venture capitalist and Trump ally, argued today that DeepSeek should be seen as 'AI's Sputnik moment,' one that raises the stakes for the global competition.
That would strengthen the case that some American AI companies have been pressing for the new administration to invest government resources into AI infrastructure (OpenAI), tighten restrictions on China (Anthropic) and ease up on regulations to ensure their developers build 'artificial general intelligence' before their geopolitical rivals.
David Sacks, fellow VC and Trump's AI czar, invoked the model to pump up Trump's approach and rebuke the Biden administration for adding too much friction to AI development.
'DeepSeek R1 shows that the AI race will be very competitive and that President Trump was right to rescind the Biden EO,' Sacks posted on X. 'I'm confident the U.S. can lead, but we can't afford to be complacent.'
It's too early to tell how Congress will respond, but the past offers some clues. In many ways, DeepSeek mirrors another Beijing tech breakthrough that blindsided both policymakers and Silicon Valley: when Huawei in 2023 seemingly sidestepped U.S. sanctions to drop a smartphone powered by a 7-nanometer chip, the most advanced China had ever produced at the time.
Just like that launch, which happened as then-Commerce Secretary Gina Raimondo was visiting China, Beijing may be sending a well-timed message to the Trump administration. In an interview last year, Deepseek's CEO said the number one challenge facing his company is export controls. Trump has ordered agencies to study existing restrictions for possible loopholes and report back by April 1.
'The story is the same in both cases, which is that the technology is legitimate and impressive, but the timing is politically motivated,' said Allen. '[This] is an attempt to try and change the political narrative in a new presidential administration — to try and say export controls have already failed, we should give up on them. That is the plan here.'
That strategy backfired during the Huawei chip saga. If anything, China hawks in Congress were further galvanized by that and other Chinese tech breakthroughs slipping past U.S. restrictions, often reacting by calling for a tougher crackdown.
Allen sees reason to not let up on China this time either. Deepseek's innovation mainly comes from a technical mechanism, he said: 'They have this architecture that allows them to extract more IQ points per chip.'
But when that multiplier is applied across China's limited chip count versus a massive supply, the result is a far greater intelligence advantage for the U.S.
By that logic, so long as the U.S. keeps denying China access to coveted American tech and fixing its workarounds, it will have the upper hand.
'Their improvements — architectural and algorithmic — are available to Western countries. And our advantages of superior chip architecture remain denied to them,' said Allen.
Deepseek's development could also mean U.S. export controls need more time to bite, not necessarily that they have failed.
'Right now, particularly with the stock market behaving the way it is, we're really at peak freak out,' Bill Drexel, a fellow at the Center for a New American Security, told POLITICO Tech host Steven Overly. '[China] has gone a lot faster than we expected. They've closed more gaps than we anticipated, but it's still going to be difficult for them to compete in the years ahead.'
Steven Overly contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
How Much Is Joe Biden's Social Security Check?
If you've ever wondered if former presidents and senators are eligible for Social Security, the answer is yes. Just as every other American who earns pays into Social Security Insurance through taxes, when they reach retirement age, they are eligible to draw benefits. Discover More: Find Out: And after 36 years as a senator, eight years as vice president and four years as president, Joe Biden is not only eligible, but collecting Social Security benefits. In fact, he's collecting well above the average Social Security recipient. How Much Is Joe Biden's Monthly Social Security Check? Unlike President Donald Trump, Joe Biden has released his annual tax returns since 1998. His 2024 return is not released yet, but his 2023 joint federal tax return, with his wife Dr. Jill Biden, states that he received $42,842 in Social Security income. That works out to approximately $3,570 per month. His wife received $21,412 in Social Security for the year of 2023. That works out to about $1,784 per month. The fact that this amount is almost exactly half of Joe Biden's suggests that she is likely drawing spousal benefits since those are capped at 50%, according to the Social Security Administration. Learn More: How Much Did Joe Biden Make as a Politician? You may be wondering why Joe Biden's Social Security is so high. The simple answer is that as a U.S. senator he drew a pretty good salary by most people's standards. Therefore, he paid and earned a high Social Security rate. Biden was elected to the U.S. Senate in 1972, when senators made $42,500 per year, according to the U.S. Senate website. That's more than $333,000 in today's dollars. Over the next few decades, his salary as senator gradually increased to $89,500 in 1987. He then ran for president and lost, but became a senator again from 1990 to 2007, finishing with a salary of $165,200. He then, of course became vice president and president. Biden first began receiving Social Security benefits in 2008 ($6,534) and in full in 2009 ($27,923). What Is the Average Social Security Check Amount? If you're wondering where Biden stands in relation to other Americans drawing Social Security benefits, he's above average. According to the Social Security Administration's (SSA) Monthly Statistical Snapshot, for the month of June 2025, the average benefit for retired workers was $2,005.05. More From GOBankingRates 5 Old Navy Items Retirees Need To Buy Ahead of Fall Mark Cuban Tells Americans To Stock Up on Consumables as Trump's Tariffs Hit -- Here's What To Buy This article originally appeared on How Much Is Joe Biden's Social Security Check?
Yahoo
7 minutes ago
- Yahoo
Analysis-Trump call to oust Intel CEO Tan could sidetrack chipmaker's turnaround
By Arsheeya Bajwa (Reuters) -Intel CEO Lip-Bu Tan is already facing an uphill battle in turning around the ailing chipmaker. Now, U.S. President Donald Trump's demand that Tan resign over his ties to Chinese firms will only distract him from that task, two investors and a former senior employee said. Trump said on Thursday that Tan was "highly conflicted" due to his Chinese connections. Reuters reported exclusively in April that Tan had invested in hundreds of Chinese firms, some of which were linked to the Chinese military. Tan may now have to mount an effort to reassure Trump that he remains the right person to revive the storied American chipmaker, pulling his focus away from the cost cuts he's trying to implement. "It is distracting," said Ryuta Makino, analyst at Intel investor Gabelli Funds, which, according to LSEG data, owns more than 200,000 shares in Intel. "I think Trump will make goals for Intel to spend more, and I don't think Intel has the capabilities to spend more, like what Apple and Nvidia are doing." AI chip market leader Nvidia and iPhone-maker Apple have committed hundreds of billions of dollars to expand domestic manufacturing, which, according to Trump, will bring jobs back home. Until recently, Intel had emerged as one of the biggest beneficiaries of the 2022 CHIPS Act, as former CEO Pat Gelsinger laid out plans to build advanced chipmaking factories. Tan, however, has significantly pared back such ambitions, as the company's goal of rivaling Taiwanese chipmaker TSMC's contract manufacturing chops have fallen short. Tan said last month that he would slow construction work on new factories in Ohio and planned to build factories only when he saw demand for Intel's chips, a move that is likely to further strain relations with Trump. The company, its board and Tan were making significant investments aligned with Trump's America First agenda, Intel said in a statement on Thursday, without any mention of Trump's demand. The statement was "bland", said David Wagner, a portfolio manager at Intel shareholder Aptus Capital Advisors, which owns Intel stock through index funds. "Either defend your leader, which will be the beginning of a difficult road ahead, or consider making a change," Wagner said. Having this play out over a few months is not something that Intel can afford, he said. Tan himself released a statement late on Thursday. "The United States has been my home for more than 40 years. I love this country and am profoundly grateful for the opportunities it has given me. I also love this company," he said, adding that the board was "fully supportive of the work we are doing to transform our company." "BUILT ON TRUST" Tan, a chip industry veteran, took the helm at Intel about six months ago, after the board ousted previous boss Pat Gelsinger over years of missteps and burgeoning losses. The company's shares are largely flat this year after losing nearly two-thirds of their value last year. Tan was the CEO of chip-design software maker Cadence Design from 2008 through December 2021. Cadence last month agreed to plead guilty and pay more than $140 million to resolve charges for selling its products to a Chinese military university believed to be involved in simulating nuclear blasts, Reuters reported. The sales to Chinese entities occurred under his leadership. Reuters reported on Wednesday that U.S. Republican Senator Tom Cotton sent a letter to Intel's board chair with questions about Tan's ties to Chinese firms and the criminal case involving Cadence. "There has been a lot of misinformation circulating about my past roles," Tan said in his statement on Thursday. "I have always operated within the highest legal and ethical standards. My reputation has been built on trust," he said. It is not illegal for U.S. citizens to hold stakes in Chinese companies unless those companies have been added to the U.S. Treasury's Chinese Military-Industrial Complex Companies List, which explicitly bans such investments. Reuters in April had found no evidence that Tan at the time was invested directly in any company on that list. But Trump's remarks have now forced the limelight on an issue that could erode investor confidence. "If you add in another layer of government scrutiny, and everybody looking into how the company is doing whatever it's doing ... that just makes it harder," said a former senior executive at Intel, who was familiar with the company's strategy under Gelsinger. The source, who declined to be named, was let go as part of Gelsinger's workforce reduction drive last year. Tan's strategy is to "get rid of all of the non-productive parts of the company and really focus on a key few products," the person said. "If (Tan) leaves, it's going to just prolong whatever Intel has to do and needs to do really quickly."
Yahoo
7 minutes ago
- Yahoo
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (F4) due to MASH and corroborating the anti-fibrotic activity of EFX seen in patients with pre-cirrhotic (F2-F3) MASH Cash, cash equivalents and short and long-term marketable securities of $1,086.2 million at June 30, 2025 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2025, and provided business updates. 'In the second quarter of 2025, we continued to build on the strong momentum established with the announcement of statistically significant reversal of cirrhosis due to MASH in the Phase 2b SYMMETRY study, supported by the peer-reviewed publication of 96-week results in the New England Journal of Medicine and additional data presentations that reinforce the anti-fibrotic activity of EFX across all stages of MASH,' said Andrew Cheng, president and CEO. 'We look forward to reporting preliminary results of our first Phase 3 trial, SYNCHRONY Real-World, in the first half of 2026 as well as a readout of SYNCHRONY Histology in the first half of 2027.' Phase 2b SYMMETRY Data Featured in the In a significant milestone for the EFX clinical program, data from the Phase 2b SYMMETRY study evaluating EFX in patients with compensated cirrhosis (F4) due to MASH was published in the New England Journal of Medicine on May 9, 2025. This peer-reviewed publication reinforces the importance of the SYMMETRY findings and positions EFX as a potential first- and best-in-class therapy with disease-modifying activity in advanced-stage MASH. New 96-Week SYMMETRY Findings Underscore Broad Potential of EFX in Late-Breaking Oral Presentation at EASL 2025 Week 96 data presented during a late-breaking oral session at EASL 2025 demonstrated the potential of EFX 50mg to reverse cirrhosis in high-need MASH subgroups, including patients with cryptogenic cirrhosis and type 2 diabetes. Data suggest EFX may benefit patients at greater risk of progression toward decompensation and end-stage liver disease, showing reversal of cirrhosis for the first time in these groups with high unmet need. The official press program of EASL 2025 highlighted the presentation of SYMMETRY results, underlining the importance of the results within the landscape of liver diseases. New Analyses from Phase 2b HARMONY Study Presented at EASL 2025 Highlight Consistent Fibrosis Improvement with EFX New insights from the Phase 2b HARMONY study demonstrated EFX's ability to improve fibrosis in pre-cirrhotic MASH (F2-F3) using both conventional pathologist scoring and advanced AI-based analysis of biopsy images. In an oral presentation, analyses of patients treated with 50mg EFX for 96 weeks showed that a majority of individuals achieved improvements across all three measures of antifibrotic response: qFibrosis® staging of biopsy images, ELF score, and liver stiffness by FibroScan®, in stark contrast to placebo patients, none of whom met all three of the same measures. AI-based analysis corroborated the treatment effect observed by conventional pathology scoring. A supporting poster provided evidence that qFibrosis® may detect fibrosis improvement earlier than conventional pathology scoring, manifested as statistically significant fibrosis regression in peri-portal and peri-sinusoidal zones. Second Quarter 2025 Financial Results Akero's cash, cash equivalents and short and long-term marketable securities as of June 30, 2025, were $1,086.2 million. Akero believes that its cash, cash equivalents and short and long-term marketable securities will be sufficient to fund its current operating plan into 2028. Research and development expenses for the three-month period ended June 30, 2025 were $69.3 million, compared to $55.3 million for the comparable period in 2024. These increases were attributable to higher expenses associated with the ongoing Phase 3 SYNCHRONY Histology, Real-World, and Outcomes studies, and manufacture of clinical supplies for Phase 3 and potential marketing applications, as well as higher expenses for personnel. General and administrative expenses for the three-month period ended June 30, 2025 were $11.6 million, compared to $10.4 million for the comparable period in 2024. These increases are attributable to higher expenses for personnel, professional services and other costs associated with operating as a public company. Total operating expenses were $80.9 million for the three-month period ended June 30, 2025, compared to $65.7 million for the comparable period in 2024. About MASHMASH is a serious form of MASLD that is estimated to affect 17 million Americans. MASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. Approximately 20% of patients with MASH are expected to progress to cirrhosis, which has a higher risk of mortality. There are no approved treatments for compensated cirrhosis due to MASH, one of the fastest growing causes of liver transplants and liver cancer in the US and Europe. About Cirrhosis Due to MASH Cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis) is a life-threatening disease with high risk of liver failure, cancer, and death. By 2030, an estimated 3 million Americans are projected to have cirrhosis due to MASH. About EFX Efruxifermin (EFX), Akero's lead product candidate for MASH, is currently being evaluated in three ongoing Phase 3 studies. In multiple Phase 2 studies, EFX has been observed to reverse fibrosis (including compensated cirrhosis due to MASH), resolve MASH, reduce non-invasive markers of fibrosis and liver injury, and improve insulin sensitivity and lipoprotein profile. This holistic profile offers the potential to address the complex, multi-system disease state of all stages of MASH, including improvements in lipoprotein risk factors linked to cardiovascular disease – the leading cause of death among MASH patients. Engineered to mimic the biological activity profile of native FGF21, EFX is designed to offer convenient once-weekly dosing and has been generally well-tolerated in clinical trials to date. About Akero Therapeutics Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero's lead product candidate, efruxifermin (EFX), is currently being evaluated in three Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at and follow us on LinkedIn and X for more information. Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, statements regarding Akero's business plans and objectives; the potential therapeutic effects of EFX, as well as the dosing, safety and tolerability of EFX, the future potential of EFX as a therapy with disease-modifying activity in advanced-stage MASH; upcoming milestones, including the results, and expected timing to report results from the SYNCHRONY Phase 3 program; and Akero's growth as a company and expectations regarding its uses of capital, expenses, and financial results, including the expected cash runway. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Akero's product candidate development activities and planned clinical trials; Akero's ability to execute on its strategy; positive results from any of its clinical studies may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Akero's ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors'' in Akero's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in Akero's other filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Akero undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contact:Christina Media Contact:Peg Akero Therapeutics, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands) June 30, 2025 December 31, 2024 Assets Cash, cash equivalents and short-term marketable securities $ 742,315 $ 743,078 Other current assets 22,285 27,302 Non-current assets 344,552 55,506 Total assets $ 1,109,152 $ 825,886 Liabilities and Stockholders' Equity Current liabilities $ 60,401 $ 39,754 Non-current liabilities 22,932 36,020 Stockholders' equity 1,025,819 750,112 Total liabilities and stockholders' equity $ 1,109,152 $ 825,886 Akero Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 69,254 $ 55,322 $ 138,821 $ 105,972 General and administrative 11,619 10,419 22,934 19,723 Total operating expenses 80,873 65,741 161,755 125,695 Loss from operations (80,873 ) (65,741 ) (161,755 ) (125,695 ) Interest expense (1,172 ) (1,231 ) (2,326 ) (2,222 ) Interest and other income, net 11,540 10,985 22,851 18,586 Net loss $ (70,505 ) $ (55,987 ) $ (141,230 ) $ (109,331 ) Comprehensive loss $ (70,602 ) $ (56,169 ) $ (141,190 ) $ (109,862 ) Net loss per common share, basic and diluted $ (0.86 ) $ (0.81 ) $ (1.76 ) $ (1.70 ) Weighted-average number of shares used in computing net loss per common share, basic and diluted 81,721,387 69,160,484 80,197,494 64,234,122 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤